Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder

International Journal of Neuropsychopharmacology

Volumn 16, Issue 2, 2013, Pages 301-311

  Duncan, Wallace C ^a   Sarasso, Simone ^b   Ferrarelli, Fabio ^b   Selter, Jessica ^a   Riedner, Brady A ^b   Hejazi, Nadia S ^a   Yuan, Peixiong ^a   Brutsche, Nancy ^a   Manji, Husseini K ^c   Tononi, Giulio ^b   Zarate, Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

biomarker; brain derived neurotrophic factor; major depressive disorder; N methyl d Aspartate receptor; sleep slow wave activity

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; KETAMINE;

ACTION POTENTIAL; ADULT; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CLINICAL ARTICLE; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD; NERVE CELL PLASTICITY; NONREM SLEEP; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SLOW WAVE SLEEP;

EID: 84875922951     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000545     Document Type: Article

References (46)

1. aan het Rot M, Collins KA, Murrough JW, Perez AM, et al. (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry 67, 139-145.
2. Allaman I, Fiumelli H, Magistretti PJ, Martin JL (2011). Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology (Berlin) 216, 75-84.
3. Altar CA, Whitehead RE, Chen R, Wortwein G, et al. (2003). Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biological Psychiatry 54, 703-709.
4. Autry AE, Adachi M, Nosyreva E, Na ES, et al. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475, 91-95.
5. Berman RM, Cappiello A, Anand A, Oren DA, et al. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47, 351-354.
6. Bunney BG, Bunney WE (2011). Rapid-Acting antidepressant strategies: mechanisms of action. International Journal of Neuropsychopharmacology. Published online 7 July 2011. doi:http://dx.doi.org/10.1017/S1461145711000927.
7. Campbell IG, Feinberg I (1996). NREM delta stimulation following MK-801 is a response of sleep systems. Journal of Neurophysiology 76, 3714-3720.
8. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, et al. (2010). A randomized add-on trial of an N-methyl-D-Aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry 67, 793-802.
9. Esser SK, Hill SL, Tononi G (2007). Sleep homeostasis and cortical synchronization: I. Modeling the effects of synaptic strength on sleep slow waves. Sleep 30, 1617-1630.
10. Faraguna U, Vyazovskiy VV, Nelson AB, Tononi G, et al. (2008). A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. Journal of Neuroscience 28, 4088-4095.
11. Feinberg I, Campbell IG (1993). Ketamine administration during waking increases delta EEG intensity in rat sleep. Neuropsychopharmacology 9, 41-48.
12. Gaillard JM, Tissot R (1975). EEG sleep studies of insomniacs under flunitrazepam treatment. International Pharmacopsychiatry 10, 199-207.
13. Gorgulu Y, Caliyurt O (2009). Rapid antidepressant effects of sleep deprivation therapy correlates with serum BDNF changes in major depression. Brain Research Bulletin 80, 158-162.
14. Hemmeter UM, Hemmeter-Spernal J, Krieg JC (2010). Sleep deprivation in depression. Expert Reviews of Neurotherapeutics 10, 1101-1115.
15. Huber R, Tononi G, Cirelli C (2007). Exploratory behavior, cortical BDNF expression, and sleep homeostasis. Sleep 430, 78-81.
16. Hughes JR (1996). A review of the usefulness of the standard EEG in psychiatry. Clinical Electroencephalography 27, 35-39.
17. Husain SS, Kevan IM, Linnell R, Scott AI (2004). Electroconvulsive therapy in depressive illness that has not responded to drug treatment. Journal of Affective Disorders 83, 121-126.
18. Ibrahim L, DiazGranados N, Franco-Chaves J, Brutsche N, et al. (2012). Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs. add-on riluzole: results from a four-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37, 1526-1533.
19. Johnson LC, Hanson K, Bickford RG (1976). Effect of flurazepam on sleep spindles and K-complexes. Electroencephalography and Clinical Neurophysiology 40, 67-77.
20. Karege F, Perret G, Bondolfi G, Schwald M, et al. (2002a). Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Research 109, 143-148.
21. Karege F, Schwald M, Cisse M (2002b). Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neuroscience Letters 328, 262-264.
22. Knott V, McIntosh J, Millar A, Fisher D, et al. (2006). Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-D-Aspartate (NMDA) receptor antagonist. Pharmacology, Biochemistry, and Behavior 85, 228-242.
23. Knott V, Millar A, McIntosh J, Shah DK, et al. (2011). Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention. Biological Psychiatry 88, 83-93.
24. Kossel AH, Cambridge SB, Wagner U, Bonhoeffer T (2001). A caged Ab reveals an immediate/instructive effect of BDNF during hippocampal synaptic potentiation. Proceedings of the National Academy of Sciences USA 98, 14702-14707.
25. Li N, Lee B, Liu RJ, Banasr M, et al. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964.
26. Lu B (2003). BDNF and activity-dependent synaptic modulation. Learning and Memory 10, 86-98.
27. Machado-Viera R, Yuan P, Brutsche N, DiazGranados N, et al. (2009). Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-Aspartate antagonist. Journal of Clinical Psychiatry 70, 1662-1666.
28. Maeng S, Zarate Jr. CA (2007). The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Current Psychiatry Reports 9, 467-474.
29. Messaoudi E, Kanhema T, Soule J, Tiron A, et al. (2007). Sustained Arc/Arc3.1 synthesis controls long-term potentiation consolidation through regulation of local actin polymerization of the dentate gyrus in vivo. Journal of Neuroscience 27, 10445-10455.
30. Messaoudi E, Ying SW, Kanhema T, Croll SD, et al. (2002). Brain-derived neurotrophic factor triggers transcription dependent, late phase long-term potentiation in vivo. Journal of Neuroscience 22, 7453-7461.
31. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
32. Pagnin D, de Queiroz V, Pini S, Cassano GB (2004). Efficacy of ECT in depression: a meta-Analytic review. Journal of Electroconvulsive Therapy 20, 13-20.
33. Pan W, Banks WA, Fasold MB, Bluth J, et al. (1998). Transport of brain derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37, 1553-1561.
34. Pittenger C, Coric V, Banasr M, Bloch M, et al. (2008). Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 22, 761-786.
35. Preskorn SH, Baker B, Kolluri S, Menniti FS, et al. (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-Aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder. Journal of Clinical Psychopharmacology 28, 631-637.
36. Rechtschaffen A, Kales A (1968). A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Washington, DC: US Government Printing Office.
37. Reus GZ, Stringari RB, Ribeiro KF, Ferraro AK, et al. (2011). Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behavioural Brain Research 221, 166-171.
38. Riedner BA, Vyazovskiy VV, Huber R, Massimini M, et al. (2007). Sleep homeostasis and cortical synchronization: III. A high-density EEG study of sleep slow waves in humans. Sleep 30, 1643-1657.
39. Schloesser RJ, Huang LD, Klein PS, Manji HK (2008). Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacolgy 33, 110-113.
40. Sen S, Duman R, Sanacora G (2008). Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-Analyses and implications. Biological Psychiatry 64, 527-532.
41. Valentine GW, Mason GF, Gomez R, Fasula M, et al. (2011). The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Research 191, 122-127.
42. Vyazovskiy VV, Cirelli C, Pfister-Genskow M, Faraguna U, et al. (2008). Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep. Nature Neuroscience 11, 200-208.
43. Vyazovskiy VV, Riedner BA, Cirelli C, Tononi G (2007). Sleep homeostasis and cortical synchronization: II. A local field potential study of sleep slow waves in the rat. Sleep 30, 1631-1642.
44. Zarate Jr. CA, Payne JL, Quiroz J, Sporn J, et al. (2004). An open-label trial of riluzole in patients with treatment-resistant major depression. American Journal of Psychiatry 161, 171-174.
45. Zarate Jr. CA, Singh JB, Carlson PJ, Brutsche NE, et al. (2006a). A randomized trial of an N-methyl-D-Aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63, 856-864.
46. Zarate Jr. CA, Singh JB, Quiroz JA, De Jesus G, et al. (2006b). A double-blind, placebo-controlled study of memantine in the treatment of major depression. American Journal of Psychiatry 163, 153-155.